Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508763 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL2438588 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL21979446 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL2437801 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL5930119 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL23092514 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL3169175 | 0.88 | SLC7A5 (0.42) | KMT2ASLC7A5L3MBTL1 | |
| SCHEMBL13536230 | 0.88 | CTRB1 (0.51) | NPC1RAB9AKMT2ACTRB1L3MBTL1 | |
| SCHEMBL13536301 | 0.88 | NPC1 (0.41) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL12195833 | 0.88 | NPC1 (0.41) | NPC1RAB9ACYP1A2KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2185561-B1 | 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo(1,2-a)-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2011-06-15 | — | — | EP | disclosed |
| US-20100197668-A1 | 1,2,3,4-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLO[1,2-a][1,4]-DIAZEPINE-7-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | US | disclosed |
| EP-2185561-A2 | 1,2,3,4-TETRAHYDROPYRROLOÝ1,2-A¨PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLOÝ1,2-A¨Ý1,4¨-DIAZÉPINE-7-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009044007-A2 | 1,2,3,4-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLO[1,2-A][1,4]-DIAZÉPINE-7-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | WO | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | NPC1 383/4885RAB9A 1827/4885CYP1A2 547/4885 |
| US-20100197668-A1 | 1,2,3,4-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLO[1,2-a][1,4]-DIAZEPINE-7-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CNR2, GRIK5, CNR1 | NPC1 2166/4885RAB9A 3364/4885CYP1A2 119/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | NPC1 1369/4885RAB9A 2531/4885CYP1A2 3724/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NPC1 1369/4885RAB9A 2531/4885CYP1A2 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.